Decision spine
Frames the controlling thesis, evidence status, buyer implications, and research-use limits.
Rare Diseases
Zemi Dossier
Research-use only
AI Multi-Omics Variant-to-Rescue
A decision package on converting unsolved genetic variants into testable rescue logic across multi-omics, functional modeling, and therapeutic strategy.
Decision this dossier helps answer
Which variant-to-function programs have enough evidence to justify rescue experiments, and what readout would falsify the rescue thesis?
Problem this dossier solves
The value is not variant prediction; it is a rescueable mechanism.
The dossier converts variant uncertainty into a sequence of evidence gates: functional effect, disease relevance, model fidelity, rescue plausibility, and endpoint logic. The decision package is built to show when a variant is actionable enough to test, not merely interesting enough to classify.
What is moving: current field evidence and platform activity
What is unresolved: decision-grade proof, endpoint logic, and failure modes
What Zemi solves: evidence-gated next-study strategy
Full decision package
121-page research report plus 40-sheet Evidence & Decision Workbook
Buy now
$3,500$5,500Launch price
Controlling thesis
The value is not variant prediction; it is a rescueable mechanism.
The dossier converts variant uncertainty into a sequence of evidence gates: functional effect, disease relevance, model fidelity, rescue plausibility, and endpoint logic. The decision package is built to show when a variant is actionable enough to test, not merely interesting enough to classify.
A Zemi Dossier turns uncertain emerging research into a decision package: what is known, what is inferred, what is hypothetical, what would falsify the thesis, and what should be built, funded, avoided, monitored, or validated next.
Research report preview
First 30 pages of the actual AI Multi-Omics Variant-to-Rescue research report.
The public page shows the real document style, density, evidence posture, and decision framing before a buyer requests access to the full Zemi Dossier package.
Research report
The research report is the argument. It is not the whole product.
The PDF research report is the structured argument: field status, evidence maturity, buyer implications, falsifiable hypotheses, power-calculated next studies, strategic recommendations, limitations, and traceability posture.
Inspectable infrastructure
Pairs the report with claim ledgers, evidence tables, power rows, audit surfaces, and decision tools.
Executable next studies
Links hypotheses to endpoint logic, assumptions, sample-size logic, budget, and timeline planning.
Research report table of contents
Public TOC generated from the source report.
The full research report is delivered as a licensed PDF. This table shows the decision structure without publishing the full product.
| Section | What it covers | Buyer value |
|---|---|---|
| Executive Summary | Condenses the dossier thesis, evidence posture, buyer implications, and next-study priorities. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Decision Brief — Read This First | Turns the report into immediate buyer triage: what matters now, what is still uncertain, and what to do next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Scope & Evidence-Integrity Statement | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| Decision Snapshot Overview | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Cheat Sheet | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Dashboard | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Source Quality Dashboard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Lets the buyer audit support strength before relying on the package. |
| Variant to Rescue Cascade Model | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Gate-Product Math — Why the Binding Gate, Not Efficiency, Sets the Ceiling | Defines the governing argument and the evidence gates that would support or falsify it. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Why Variant to Rescue Stalled | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Five-Gate Frontier — 2026 Deep-Dive | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| 2026 Current-Signal Refresh | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross-Gate & Cross-Disease Convergence Map | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| The Convergent-Node Frontier | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Evidence Maturity & Modality Matrix | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Competitive Landscape | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Connects research claims to practical diligence and monitoring decisions. |
| The Platform-Designation Paradox — the Sarepta Lesson for the Node-Platform | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Key Findings | Summarizes the most decision-relevant findings and their implications for the dossier thesis. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Gate 2 — Reversibility window | Defines the governing argument and the evidence gates that would support or falsify it. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 1 — Causal resolution | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 3 — Modality–mechanism match | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 4 — Delivery-within-window | Defines the governing argument and the evidence gates that would support or falsify it. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 5 — Evidentiary translation | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Convergent node — Lysosomal/TFEB | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Convergent node — UFMylation | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Convergent node — Method | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Economics — N-of-1 to platform | Connects research maturity to competitive position, program strategy, and diligence watchpoints. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Regulatory — Plausible mechanism (draft) | Explains which biological signals matter for interpreting the field and discriminating between programs. | Shows where the thesis could fail or require more validation before action. |
| Quantitative Evidence | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Lets the buyer audit support strength before relying on the package. |
| Key Findings & Quantitative Synthesis | Summarizes the most decision-relevant findings and their implications for the dossier thesis. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Quantitative Frontier Synthesis | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross-Domain Synthesis | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Transportability Theorem | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Competing Interpretations Adjudicated | Compares alternative readings of the evidence and explains why the dossier weights one interpretation over another. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Modality Permanence-Spectrum Map | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Mechanistic Deep-Dive | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
Evidence & Decision Workbook
The workbook is the decision engine.
A locked public preview of selected workbook-derived sheets: sheet structure, decision modules, power rows, traceability, and audit posture. Licensed buyers receive the full workbook files.
Read-only workbook preview with clipped values and no formulas. Licensed buyers receive the full Evidence & Decision Workbook with editable assumptions and working files.
Workbook inventory
Delivered workbook sheets.
Full inventories belong on dossier pages, not the homepage. Sheet names below are extracted from the actual workbook file.
| # | Workbook sheet | What it does |
|---|---|---|
| 1 | Workbook Guide | Navigation layer for using the workbook, understanding sheet roles, and following the decision package. Public preview exposes Sheet, Contents fields and clipped entries such as Claim Ledger, 89 customer-facing claims: text,., Evidence Table. |
| 2 | Claim Ledger | Claim-by-claim ledger showing verdicts, source support, inference status, and decision relevance. Public preview exposes Claim, Claim text, Section, Gate(s) fields and clipped entries such as Finding 1 — Extracellular vesicles., Extracellular vesicles. |
| 3 | Evidence Table | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes PMID:41316820, Potent Liver-Tropic mRNA Lipid., Advanced materials (Deerfield., 2026 fields and clipped entries such as PMID:42127219,. |
| 4 | Source-Support Verdicts | Independent check on whether key claims are actually supported by cited sources. Public preview exposes Claim, Claim (short), Primary citation, Verdict fields and clipped entries such as Finding 1 — Extracellular vesicles., Extracellular vesicles (EVs).,. |
| 5 | Quantitative Evidence | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes Claim, Claim (short), Population, Intervention fields and clipped entries such as Finding 1 — Extracellular vesicles., Extracellular vesicles. |
| 6 | Source Quality Summary | Summary of source strength, gaps, and areas where conclusions depend on weaker evidence. Public preview exposes High-quality citations (per claim), 0, 35, Rigorous primary/premier-review. fields and clipped entries such as Moderate-quality citations (per. |
| 7 | Modality-Gate Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Modality, G1 Cause, G2 Reversibility, G3 Modality-match fields and clipped entries such as Splice-switching ASO, Splice lesion class matches;.,. |
| 8 | Causal-Cascade-Gate Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Gate, Question, Arbiter, Dominant failure mode fields and clipped entries such as G1 Causal Resolution, Is THIS variant the true driver?, AI. |
| 9 | Disease-Variant Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Disease, Gene / variant, Defect class, Functional model fields and clipped entries such as DFNA2 hearing loss, KCNQ4 c.961G>A, GoF/dominant. |
| 10 | Modality-Delivery Tracker | Captures failure modes and constraints that could invalidate or narrow a program. Public preview exposes Platform, Type, Efficiency (verified), Tissue fields and clipped entries such as Dual-AAV ABE8e, Base editor, 21.4-28.9% (cochlea). |
| 11 | Asset-Sponsor Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Sponsor / program, Modality, Indication, Stage fields and clipped entries such as CHOP / Penn (Ahrens-Nicklas), Individualized base editing, CPS1. |
| 12 | Trial-Catalyst Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes ID, Intervention, Indication, Phase fields and clipped entries such as NCT07215416, ASO (ATM), Ataxia-telangiectasia. |
| 13 | Failure-Mode Tracker | Captures failure modes and constraints that could invalidate or narrow a program. Public preview exposes Editing mosaicism (sufficiency), Delivery (G4), Node-dependent sufficiency, Match efficiency target to node. fields and clipped entries such as In-utero. |
| 14 | Convergent-Node Atlas | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Convergent node, Member genes / diseases, Shared reversible phenotype, Candidate node-level rescue fields and clipped entries such. |
| 15 | Biomarker-Endpoint Map | Tracks biomarkers or readouts that determine whether the thesis is moving toward testable evidence. Public preview exposes Biomarker, Node / disease, Role, Anchor fields and clipped entries such as Lysosomal clearance / cholesterol, TFEB/lysosomal node,. |
| 16 | Regulatory Tracker | Tracks regulatory, endpoint, reimbursement, or qualification requirements that shape testing strategy. Public preview exposes Channel, Status, Applicability, Note fields and clipped entries such as IND / IDE, In force, First-in-human entry. |
| 17 | Figure Source Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes Figure ID, Title, Family, Anchor section fields and clipped entries such as FIG-01, Functional rescue by developmental., Gene Therapy. |
| 18 | Figure Attempt Ledger | Figure and numeric reproduction log for validating calculations, chart inputs, or displayed values. Public preview exposes Figure ID, File, Backend, Evidence grade fields and clipped entries such as FIG-01, fig_window_timeline.png, deterministic. |
| 19 | Hypotheses Ledger | Maps hypotheses to evidence state, falsification logic, endpoints, and next-study design. Public preview exposes ID, Tier, Title, Category fields and clipped entries such as H1, F1, The TFEB/TFE3 lysosomal-biogenesis.. |
| 20 | Most Valuable Next Studies | Prioritizes next studies that could change the decision, including endpoints and evidence gates. Public preview exposes Study, Research question, Population / model, Comparator fields and clipped entries such as 1 Convergent-node atlas + cross-gene., Does. |
| 21 | Verification & Search Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes Number concordance, Every quantitative claim. fields and clipped entries such as Fresh search (base), 14 Europe PMC (2026) queries +. |
| 22 | Search Query Log | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Scan, Database, Query (verbatim), Hits fields and clipped entries such as REV-2 (to 2026-06-13), PubMed, AI variant interpretation. |
| 23 | Excluded Claims | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Citation, Claim (short), Original bucket, Disposition (re-adjudicated) fields and clipped entries such as NCT:NCT07543991, Phase. |
| 24 | Salvage Ledger | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Source element, Decision, Rationale fields and clipped entries such as Variant->function->rescue framing, REUSE, Correct and. |
| 25 | Power Calculations | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. Public preview exposes hypothesis_id, study_id, endpoint, test_type fields and clipped entries such as H1, F1-NODE-RESCUE, Fraction of patient lines. |
| 26 | VRMS_Input_Template | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes G5_evidence_maturity, 0-4, 3, Does the evidence TYPE license. fields and clipped entries such as disease_temporal_structure, Durable | Fluctuating. |
| 27 | VRMS_Feature_Score | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Modality, G1 cause-fit, G2 window-fit, G3 match-fit fields and clipped entries such as ASO/splice-switch, Base editing. |
| 28 | VRMS_Defect_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Metabolic, Pathway/node-directed, Gene replacement, OK fields and clipped entries such as Pathway, Pathway/node-directed, Gene replacement. |
| 29 | VRMS_Class_Output | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes G5_evidence_maturity (0-4), 3, does evidence TYPE license the. fields and clipped entries such as disease_temporal_structure, Durable, Durable |. |
| 30 | VRMS_Decision_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes 3, Confidence guard (no naive argmax), any gate blank OR., MIXED / LOW CONFIDENCE —. fields and clipped entries such as Permanence-match override,. |
| 31 | VRMS_Minimum_Assay_Panel | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes G5 evidence, Evidence-type ladder., Does the evidence license the., Flag maturity; keep claim. fields from this sheet. |
| 32 | VRMS_Archetype_Cards | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes NPC1 lysosomal node, Metabolic/pathway, 2, 3 fields and clipped entries such as PLCG2 protective resilience, Protective-modifier, Durable. |
| 33 | VRMS_Validation_Log | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Training target, Modality choice that maximizes. fields and clipped entries such as Validation cohort, Held-out patient-derived lines., Held-out. |
| 34 | VRMS_Traceability_Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes Classifier element, Basis / rationale, Source IDs, Status fields and clipped entries such as Five-gate input set, The Variant-to-Rescue. |
| 35 | Score Basis | Explains how scores or ratings were assigned so the decision instrument can be inspected. Public preview exposes Durable-moat leverage (Buyer., Low/Med/High, how defensible/compounding the., Expert; tied to. fields and clipped entries such as Evidence. |
| 36 | Competitive Landscape | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Company, Asset, Modality, Target / indication fields and clipped entries such as Beam Therapeutics, BEAM-302, DNA base editing (in vivo). |
| 37 | Version Registry | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes v1.0 (base), 2026-06-07, Tier C build (audit-passed ~95 on., 5-gate cascade, 'correctable !=. fields and clipped entries such as v2.0. |
| 38 | Audit Issues Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes #, Issue, Severity, Status fields and clipped entries such as Strict prose below 25k floor (base., Major, CLOSED. |
| 39 | Traceability Certificate | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes Claim ID, Claim text (full), Report section, Primary source ID fields and clipped entries such as Finding 1 — Extracellular vesicles.,. |
| 40 | Traceability Summary | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes Evidence window, late-2025 to mid-2026. fields and clipped entries such as Total source claims audited, Customer-facing claims kept. |
Power-calculated next studies
Power calculations are the execution bridge.
Power calculations are planning-grade research calculations for endpoint logic, assumptions, sample size, budget, and timeline. They do not prove hypotheses or constitute clinical protocol.
| Hypothesis | Primary endpoint | Test | Effect | α | Power | Computed n | Design n |
|---|---|---|---|---|---|---|---|
| H1 | Fraction of patient lines reaching >=50% node-phenotype normalization... | two-proportion | 0.55 | 0.05 | 0.80 | 29 | 30 |
| H2 | ABR threshold improvement (dB), early-redosable low-efficiency vs lat... | two-sample-means | 13.0 | 0.05 | 0.80 | 10 | 12 |
| H3 | Synaptic density / dopaminergic survival, stabilization vs inhibition... | two-sample-means | 26.0 | 0.05 | 0.80 | 10 | 6 |
| H4 | AUC of AI pathogenicity score for predicting reversibility (rescue-re... | AUC (Hanley-McNeil, external) | 0.65 | 0.05 | 0.80 | 100 | 80 |
| H5 | Acceptance probability of a disease-agnostic node biomarker under pla... | single-proportion-precision | 0.5 | 0.05 | precision sizing — CI half-width | 43 | 43 |
Release audit discipline
Audit posture is part of the product.
Public pages do not publish exact audit scores. They should state the release discipline, revision posture, and limitations without implying peer review or validated clinical guidance.
Research-use decision package
Not medical advice, clinical guidance, investment advice, or a clinical protocol.
Known / inferred / hypothetical
The package separates cited evidence from inference and frontier hypothesis generation.
Audit-gated and revision-controlled
Adversarial audit checks source support, formulas, figures, limitations, and release readiness.
Buy this dossier
Full decision package — 121-page report + 40-sheet workbook
Buy now
- Decision research report (121 pages, PDF)
- Evidence & Decision Workbook (40 sheets, .xlsx) — claims, source-support verdicts, power calculations, traceability, and audit log
- Live, editable power-calculated next studies
$3,500$5,500Launch price